Rafferty Asset Management
ITCI

Rafferty Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Rafferty Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,484
Closed -$328K – 1105
2025
Q1 		$328K Sell
2,484
-1,746
-41% -$218K ﹤0.01% 939
2024
Q4 		$353K Sell
4,230
-1,590
-27% -$131K ﹤0.01% 992
2024
Q3 		$426K Sell
5,820
-131
-2% -$9.85K ﹤0.01% 979
2024
Q2 		$408K Sell
5,951
-1,566
-21% -$109K ﹤0.01% 998
2024
Q1 		$520K Buy
7,517
+725
+11% +$49.8K ﹤0.01% 965
2023
Q4 		$486K Buy
6,792
+526
+8% +$30.3K ﹤0.01% 987
2023
Q3 		$326K Buy
6,266
+1,410
+29% +$82.1K ﹤0.01% 1008
2023
Q2 		$307K Buy
4,856
+543
+13% +$33.8K ﹤0.01% 1037
2023
Q1 		$234K Sell
4,313
-154
-3% -$7.45K ﹤0.01% 1085
2022
Q4 		$236K Sell
4,467
-254
-5% -$12.7K ﹤0.01% 1053
2022
Q3 		$220K Buy
4,721
+251
+6% +$13.1K ﹤0.01% 1082
2022
Q2 		$255K Sell
4,470
-2,976
-40% -$169K ﹤0.01% 973
2022
Q1 		$456K Sell
7,446
-1,420
-16% -$73.7K ﹤0.01% 1030
2021
Q4 		$464K Sell
8,866
-683
-7% -$28.7K ﹤0.01% 1073
2021
Q3 		$356K Buy
+9,549
New +$332K ﹤0.01% 1107
2021
Q1 		– Sell
-11,666
Closed -$371K – 1172
2020
Q4 		$371K Buy
+11,666
New +$307K ﹤0.01% 757
2020
Q1 		– Sell
-6,476
Closed -$222K – 830
2019
Q4 		$222K Sell
6,476
-6,096
-48% -$73.2K ﹤0.01% 828
2019
Q3 		$94K Buy
+12,572
New +$121K ﹤0.01% 793

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Rafferty Asset Management's ITCI Position: Q2 2025 in Review

Rafferty Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 2,484 shares — an estimated $328K sold.

Rafferty Asset Management first reported a position in ITCI in Q3 2019 and held it in 18 quarters. The position peaked at $520K in Q1 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Rafferty Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Rafferty Asset Management sold 2,484 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $328K.
  • Rafferty Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2019 and held it in 18 quarters.
  • Rafferty Asset Management's Intra-Cellular Therapies Inc. position peaked at $520K in Q1 2024.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Rafferty Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.